How Are People Losing Weight on Ozempic?

Last reviewed: May 19, 2026

Last updated: May 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

People lose weight on Ozempic primarily through GLP-1 receptor activation, which reduces appetite, slows stomach emptying, and increases feelings of fullness. Clinical trials show average weight loss of 10–22% over 68 weeks, depending on dose and individual factors. This mechanism differs substantially from older weight-loss approaches, making it essential to understand how it works before considering treatment.

Beyond the basic mechanism, individual metabolic variation, genetic factors, and biomarker profiles significantly influence how effectively GLP-1 medications work for any given person. PlexusDx integrates this precision-wellness framework, helping patients and providers move beyond one-size-fits-all assumptions and make evidence-informed decisions about peptide-based treatments.

The GLP-1 Appetite-Suppression Pathway

GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone that signals fullness to the brain. Ozempic mimics this hormone, binding to GLP-1 receptors in the hypothalamus and brainstem. This activation reduces hunger signals and increases satiety, leading people to eat fewer calories without conscious restriction.

Additionally, GLP-1 slows gastric emptying—the rate at which food leaves the stomach. Slower digestion prolongs feelings of fullness between meals, further reducing overall food intake. These dual mechanisms create a powerful appetite-dampening effect that often surprises patients by how naturally it reduces food cravings.

Clinical Weight-Loss Data and Individual Response Variation

Landmark clinical trials demonstrate significant weight loss across populations, yet individual responses vary considerably. Understanding these patterns helps set realistic expectations and informs whether GLP-1 therapy aligns with individual health goals.

Outcome Measure	Data Point
Average Weight Loss (Ozempic studies)	10–15% body weight over 68 weeks at therapeutic doses
Percentage Achieving ≥10% Loss	Approximately 50–70% of participants across major trials
Percentage Achieving ≥15% Loss	Approximately 30–50% depending on baseline and dose
Factors Affecting Response	Baseline BMI, genetics, diet compliance, baseline metabolic health, GLP-1 receptor expression variability

Metabolic and Genetic Factors Influencing Individual Response

Not everyone responds identically to GLP-1 therapy. Baseline metabolic health, insulin resistance, resting metabolic rate, and gut hormone signaling all influence how much weight a person loses. Genetic variation in GLP-1 receptor expression (GLP1R) and related pathways affects receptor sensitivity and medication efficacy.

PlexusDx's Precision Peptide Genetic Test examines key variants—including GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—in peptide genetic pathways. These predispositions may help provide context for understanding individual appetite-regulation patterns and inform more targeted conversations with healthcare providers about treatment candidacy and dosing strategy.

Safety Considerations and Who Should Consider GLP-1 Therapy

GLP-1 medications are FDA-approved for weight management in people with BMI ≥27 with weight-related conditions, or BMI ≥30. Common side effects include nausea, constipation, and vomiting, typically mild and transient. Serious risks—including pancreatitis, gallbladder disease, and thyroid concerns—require medical screening and ongoing monitoring by a qualified provider.

GLP-1 therapy is not appropriate for people with personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe kidney disease, or uncontrolled diabetes complications. A thorough medical evaluation is essential before starting. PlexusDx compounded GLP-1 options (semaglutide, tirzepatide) require a provider prescription and should be used only under medical supervision with regular follow-up.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that GLP-1 weight loss is not simply a calorie-reduction story—it reflects complex interactions between receptor genetics, metabolic phenotype, and lifestyle factors. Our Precision Peptide Genetic Test may help provide context for individual peptide pathway function and receptor sensitivity patterns, supporting a more nuanced clinical conversation.

The genetic test reveals predispositions in key peptide-signaling variants: GLP1R (appetite signal detection), GIPR (additional glucose-dependent hormone sensitivity), FTO (metabolic regulation), and MC4R (central appetite control). These insights should be interpreted with a qualified healthcare provider as part of comprehensive metabolic assessment—they predict individual pathway activity patterns, not exact medication response.

Understanding your genetic predispositions in peptide pathways can help frame why certain GLP-1 dosing strategies, adjunctive lifestyle measures, or alternative peptide compounds (like tirzepatide's dual GLP-1/GIP activity) may be worth discussing with your provider. This precision-wellness approach transforms generic treatment into informed, personalized decision-making.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

How Are People Losing Weight on Ozempic? | PlexusDx